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Common infrastructures and platforms are required for international collaborations in large-scale human genomic
research and policy development, such as the Global Alliance for Genomics and Health and the ‘ELSI 2.0’ initiative.
Such initiatives may require international harmonization of ethical and regulatory requirements. To enable this,
however, a greater understanding of issues and practices that relate to the ethical, legal and social implications (ELSI)
of genomic research will be needed for the different countries and global regions involved in such research. Here,
we review the ELSI practices and regulations for genomic research in six East Asian countries (China, Indonesia, Japan,
Singapore, South Korea and Taiwan), highlighting the main similarities and differences between these countries, and
more generally, in relation to Western countries. While there are significant differences in ELSI practices among these
East Asian countries, there is a consistent emphasis on advancing genomic science and technology. In addition, considerable
emphasis is placed on informed consent for participation in research, whether through the contribution of
tissue samples or personal information. However, a higher level of engagement with interested stakeholders
and the public will be needed in some countries.Introduction
Research on the ethical, legal and social implications
(ELSI) of human genetics and genomics was originally
developed in the context of the Human Genome Project
(HGP) [1,2], and it is now applied in other areas of re-
search, such as nanotechnology research and develop-
ment [3]. Over the past decade, an increasing number of
approaches linking social sciences research on bioethical
and medical practices have reflected a wider involvement
of social scientists, including ELSI researchers, in deve-
loping policies for biomedical research that are more
responsive to broader social needs [4-12].
With the rapid advances in genomic science and tech-
nology, there is a greater need to develop common infra-
structures and platforms for international collaboration
and public participation. These are necessary not only to
meet scientific needs, but also to sustain public trust and* Correspondence: go@eth.med.osaka-u.ac.jp
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One such initiative is the Global Alliance for Genomics
and Health (Global Alliance) [13], launched in 2013 and
now involving more than 170 leading organizations in
healthcare, research and disease advocacy all over the
world. It aims to ‘create a common framework of har-
monized approaches to enable the responsible, volun-
tary, and secure sharing of genomic and clinical data’
[14]. Another more ELSI-focused initiative is ELSI 2.0,
launched in 2012 and aimed at enabling ELSI research
to ‘become more coordinated, responsive to societal
needs, and better able to apply the research knowledge it
generates at the global level’ [15]. One of the major chal-
lenges they recognize is the need for international ethics
harmonization in the requirements of informed consent
and privacy protection. These requirements are under-
scored by international initiatives, including the Inter-
national Cancer Genome Consortium (ICGC) [16] and
the Public Population Project in Genomics and Society
(P3G) [17], although these tend to reflect the ethics
practices and policies in North America and Westerntral Ltd. The licensee has exclusive rights to distribute this article, in any medium,
this time, the article is available under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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countries’). This is understandable, given the geogra-
phical distribution of many of the members and experts
involved in these initiatives.
However, ethical, legal and social concerns may differ
in other global regions, and it is important to under-
stand these differences in order to facilitate international
research collaboration. Here, we aim to review current
ELSI practices and regulations relating to human gen-
omic research in a selection of East and Southeast Asian
countries, namely China, Indonesia, Japan, South Korea,
Singapore and Taiwan (hereafter, generally referred to as
‘East Asian countries’). Our focus on a selection of East
Asian countries is largely due to the availability of
experts and of policies in the public domain. In addition,
a level of demographic distribution is achieved with
these East Asian countries, and each of these is actively
engaged in genomic research and (with the exception of
Indonesia) has launched or is about to launch a popula-
tion biobank [18]. It is envisaged that other countries
in the region, including Thailand, Malaysia and the
Philippines, which are increasingly engaged in genome
research, will subsequently be included in ongoing efforts
to develop ELSI practices that facilitate international
collaboration.
A recent report on ELSI studies published in 2003 to
2008 showed that the dominant approach could be cha-
racterized as ‘downstream’, in the sense that the con-
cerns followed developments in genomic research and
practice [19]. Following the dominant approach, we first
review ELSI practices and regulations in East Asian
countries relating to the main human genomic research
centers and resources, laws and regulations for bio-
medical and genomic research, ELSI practices and chal-
lenges for ethics review and informed consent, and for
sample and data sharing (and privacy protection). We
then highlight the main differences in ELSI practices
between these East Asian countries and Western coun-
tries, particularly regarding research infrastructure, regu-
latory frameworks, ethics review and informed consent.
Finally, we discuss the progress and challenges for re-
search collaboration and for public participation in
national and international genomics projects.ELSI practices in East Asia
Here, we summarize current ELSI practices and policies
for genomic research in China, Indonesia, Japan,
Singapore, South Korea and Taiwan, highlighting specific
issues regarding ethics review and consent processes,
and data sharing and protection. For each country, the
main centers and resources for genomic research are
summarized in Table 1, and current regulations and
policies are summarized in Table 2.China
There are three main institutions in China with large
genomic databases and biobanks: the Chinese National
Human Genome Center in Shanghai (‘South Center’),
the Chinese National Human Genome Center in Beijing
(‘North Center’), and the Beijing Genomics Institute
(BGI) in Shenzhen (Table 1).
Although China has no legislation on human genome
research, it has rather strict regulations on research in-
volving human subjects and on the use of human ge-
netic resources (Table 2). Ethics review committees
(ERCs) were developed in the 1990s with the launch of
international cooperative programs to learn about insti-
tutional review board (IRB) systems for human subject
research in other countries. The first Regulations on
Ethics Review of Biomedical Research Involving Human
Subjects were issued in 1998. The Ministry of Health
(MOH; currently the National Health and Family Plan-
ning Commission) issued a revised draft in 2007, and
the revision process is still ongoing [31]. According to
these regulations, each research institution should set
up an ERC when conducting research, and ERC mem-
bers should be composed of a wide variety of internal
and external experts taking into account gender balance.
The new Interim Measures for the Administration of
Human Genetic Resources, originally issued by the Minis-
try of Science and Technology (MOST) and MOH in
1998, was drafted in October 2012 [30] and is currently
the subject of a public consultation.
The ERC system in China is established at three diffe-
rent levels: first within research institutions, then at the
municipal and provincial level, and then at the level of
the MOH. The ERC at a higher level bears the responsi-
bility for supervising the work of ERCs at lower levels.
The regulations described above require institutions and
researchers to obtain informed consent from potential
donors before collecting and storing samples. The
commercialization of genomic research can involve ex-
pedited processes that may undermine the individual
right of informed consent. In the case of biobanking, the
increasing use of general consent or even blanket con-
sent may raise questions about the sufficiency of consent
if the possibility of commercialization is not clarified at
the outset [34]. This also raises concerns about whether
researchers and ERC members are ethically qualified for
conducting and reviewing research. These concerns are
made worse by a rather unstructured oversight system
of local ERCs - each local health bureau organizes a
group of experts to conduct an annual evaluation of
ERCs, but there is no oversight of the different ERCs.
The National Clinical Specimen Biobank Project [23]
has established a biobank network of clinical biological
resources in Beijing, Shanghai and other regions. One
major biobank is the Kadoorie Study of Chronic Disease
Table 1 East Asian centers and resources for human genomic research
Country Institutes conducting large-scale
genomic researcha
National human genome
databases
National biobanksb
China • Chinese National Human Genome Center,
Shanghai (‘South Center’)
• Pan-Asia Population SNP
Database [20]
• Human Genetic Resources Platform
(2003–2007) [21]
• Chinese National Human Genome Center,
Beijing (‘North Center’)
• 1000 Genomes Project • Kadoorie Study of Chronic Disease in
China (KSCDC; 2004–2008) [22]
• Beijing Genomics Institute (BGI), Shenzhen • National Clinical Specimen Biobank
(2011–2015) [23]
Indonesia • Biotechnology Research Centre of the Science
Institute of Indonesia (LIPI)
(Individual institution-wide
databases only)
• Eijkman Institute
• Institute of Tropical Disease
• Consortium on Vaccine Research
(16 universities and research institutions)
Japan • University of Tokyo • Japanese Genotype-phenotype
Archive (JGA) [24]
• Biobank Japan (2003-) [25]
• Yokohama City University • Japanese Single Nucleotide
Polymorphisms (JSNP)
• National Center Biobank Network
(NCBN; 2012-) [26]
• RIKEN Center for Genomic Medicine (CGM) • Human Genome Variation
Database (HGVD)
• Tohoku Medical Megabank
(ToMMo; 2012-)
• Tohoku University • National Registry of Diseases
Office (NRDO)
• National Cancer Center
Singapore • Genome Institute of Singapore
• Bioinformatics Institute
• Bioprocessing Technology Institute
• National University of Singapore
• Nanyang Technological University
• National Cancer Centre
• Defence Science Office
South Korea • Korea Centers for Disease Control and
Prevention (KCDC)
• Korean Genomic Variant
Database (KGVDB)
• Korea Biobank Project (KBP; 2008-;
including Korea Biobank Network and
National Biobank of Korea (NBK)) [27,28]
Taiwan • Genomics Research Center (GRC),
Academia Sinica
• Taiwan Biobank (2005-) [29]
• National Health Research Institute (NHRI)
aA selection of major institutes is included.
bCommencement year and termination year are shown in parentheses.
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based health database [23]. The other is the Human
Genetic Resources Platform established under the lead-
ership of MOST [21]. There is little research collabo-
ration for data access or data sharing, as public distrust
of expert authorities has been an obstacle to individual
donation of samples to researchers and doctors [35].
The Interim Measures define that international colla-
borative projects involving human genetic resources
should apply the principles of mutual benefit and credit,
and any consequent patent rights that arise shall be
owned by both Chinese and foreign institutions (if any).
Another major challenge for public participation in
genomic research is concern over the misuse of geneticinformation. For example, genetic testing for thalassemia
for the recruitment of civil servants in Guangdong pro-
vince has caused genetic discrimination against people
from that province, as they are suspected to be more
likely to be thalassemia gene carriers than those living in
other areas [36-38].
Indonesia
Human genome research in Indonesia started to flourish
in the 1990s in many leading universities and also in na-
tional research institutes, such as the Biotechnology Re-
search Centre of the Science Institute of Indonesia,
Eijkman Institute and the Institute of Tropical Disease
(Table 1). Subsequently, the number of genomic research
Table 2 ELSI practices and regulations for human genomic research in East Asia
Regulationsa Responsible agencies Challenges for research collaboration
and public participation
China Interim Measures for the Administration of
Human Genetic Resources (1998) [30]
Ministry of Science and Technology;
Ministry of Health
Public concerns about the misuse of
genetic information
Public distrust of authoritiesRegulations on Ethics Review of Biomedical
Research Involving Human Subjects (2007) [31]
Ministry of Health
Indonesia National Guideline on Research Ethics: Genetic
Research (2008)
National Committee on Research Ethics Protection of rights and privacy of
indigenous populations
National Regulation on Material Transfer
Agreement (2009)
Ministry of Health Need for more integrated approach
on genome research
Low public awareness on genetic
information and related ELSI issues
Japan Ethical Guidelines for Human Genome/Gene
Analysis Research (2001)
Ministry of Education, Culture, Sports,
Science and Technology; Ministry of Health,
Labour and Welfare; Ministry of Economy,
Industry and Trade
Public concerns about privacy
protection in relation to genetic
information
Protection of Personal Information Act (2003) Consumer Affairs Agency
Singapore Guidelines for IRBs (2004) Bioethics Advisory Committee/
Ministry of Health
Public concerns about potential
discrimination, inequitable access and
conflicts of interest
Guidelines on Genetic Testing and
Research (2005)
Bioethics Advisory Committee/Ministry of
Health
National Registries of Disease Act (2007) National Registry of Diseases Office (NRDO)
Guidelines on Use of Personal Information in
Biomedical Research (2007)
Bioethics Advisory Committee/Ministry of
Health
Personal Data Protection Act (2012) Data Protection Commission
South Korea Bioethics and Biosafety Act (2005) National Bioethics Committee Low public awareness of genomic
medicine
Personal Information Protection Act (2012) Ministry of Public Administration and
Security
Guidelines for Protecting Genomic Information
in Medical Institutions (2012)
Ministry of Public Administration and
Security; Ministry of Health and Welfare
Guidelines for Protecting Genomic Information
(2013)
National Project for Personalized Genomic
Medicine 21 (PGM21) [32]
Taiwan Guidelines for Collection and Use of Human
Specimens for Research (2002)
Ministry of Health and Welfare Insufficient public communication
and trust
Strict legal regulations due to privacy
concerns from human right groups
Regulations on Human Trials (2009) Ministry of Health and Welfare
Personal Information Protection Act (2010) Ministry of Justice
Human Biobank Management Act (2010) [33] Ministry of Health and Welfare
Human Subjects Research Act (2011) Ministry of Health and Welfare
aYear of establishment of regulation, or enactment of law, is shown in parentheses.
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from the government is usually based on routine
medium-scale annual grants, and national large-scale pro-
jects such as the National Consortium on Vaccine Re-
search are still uncommon. There are no public biobanks
or databases for genomic research in the country yet, and
each center manages its own bio-repository and databases.
While Indonesia does not have specific legislation on
genetic data, a number of related laws and guidelines on
human rights, medical practice and medical education
have specific emphasis on group consent targeting hu-
man specimen collection from indigenous tribes or tra-
ditional communities (Table 2). They also restrict theconduct of genetic screening and prenatal diagnostics on
these populations or communities.
The Indonesian research ethics committees are usually
institutional (IRBs), affiliated to hospitals, medical schools,
or research institutions, and mainly focus on institutional
needs. Currently there are 54 IRBs. Larger and more
established IRBs accept submission from other institu-
tions. While IRBs are established as independent bodies,
they are still highly dependent on their main institutions
for funding and staff. The National Research Ethics Com-
mittee (KNEPK) was established by the Ministry of Health
in 2003. Besides endorsing the establishment of IRBs,
KNEPK provides supervision for local IRBs, facilitating
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search ethics guidelines and facilitating national and inter-
national networks on health research ethics. In this sense,
it provides consultation for IRBs in special cases. There
have been recommendations for KNEPK to become the
national supervisory body for IRBs, commencing in 2015.
To ensure quality of review, several IRBs have joined the
Strategic Initiative for Developing Capacity in Ethical
Review (SIDCER) Recognition Programme [39] facilitated
by WHO-TDR (World Health Organization, Special
Programme for Research and Training in Tropical
Diseases) [40] and FERCAP (Forum for Ethical Review
Committees in the Asian and Western Pacific Region) [41].
As a consequence of the disagreement between the
Indonesian government and WHO regarding H5N1 bio-
specimen transfer in 2006, the international transfer of
biomaterials became a sensitive issue relating to specimen
ownership, property rights, benefit sharing and inter-
national research collaboration [42,43]. The dispute led to
the revision of the Health Law (2009) and the enactment
of the Ministry of Health Regulation on Material Transfer
Agreement (2009). This is intended to ensure fairer bene-
fit sharing, protection of the nation’s sovereignty and
strengthening of local researchers’ bargaining position in
international research collaborations. The disagreement
resulted in a resolution from Indonesia, backed by
Malaysia, Thailand and other developing countries to ad-
vocate recognition of principles of sovereign right over
genetic resources [44]. This led to the promulgation of the
Nagoya Protocol on Access to Genetic Resources and the
Fair and Equitable Sharing of Benefits Arising from their
Utilization (the Nagoya Protocol, first adopted in Nagoya,
Japan) as a supplement to the Convention on Biological
Diversity in 2010. A law was passed to give regulatory
effect to the Nagoya Protocol in May 2013. Although the
protocol focuses on natural resources in general, it uses
the H5N1 issue to endorse strengthening of ‘a fair, trans-
parent, equitable, efficient, and effective system’ for both
specimen and benefit sharing. The law demonstrates the
country’s focus on protection against biopiracy of genetic
resources, including clinical specimens.
Due to great socio-economic disparities within patient
populations, IRBs must remain vigilant in ensuring that
participation of research subjects is voluntary and on an
informed basis. There is also the significant challenge in
protecting indigenous populations from exploitation,
whether by researchers in Indonesia or overseas. This
situation requires public education on international re-
search collaborations and empowerment by a wide range
of research and policy experts.
Japan
Many research institutions in Japan, including the
University of Tokyo, Yokohama City University and theRIKEN Center for Genomic Medicine (CGM), conduct
personal genome analysis, for example, through whole
exome sequencing (Table 1). Genome cohort studies in
the Tohoku Medical Megabank Organization (ToMMo)
were launched in 2012, and ToMMo has initiated a
three-generation cohort study and a community resident
cohort study involving 150,000 participants. Whole
genome sequencing has already been completed for
1,000 participants at the end of 2013.
Human genome research in Japan is regulated by the
Ethical Guidelines for Human Genome/Gene Analysis
Research (‘Genome Guidelines’), which were established
in 2001 on the basis of Fundamental Principles of
Research on the Human Genome (Bioethics Committee,
Council for Science and Technology, 2000) issued by the
Ministry of Education, Culture, Sports, Science and
Technology (MEXT), the Ministry of Health, Labour
and Welfare (MHLW) and the Ministry of Economy,
Trade and Industry (METI) (Table 2). Such guidelines
permit researchers to obtain ‘comprehensive consent’,
whereby informed consent is granted not only to a spe-
cific and defined project, but also extends to other gen-
ome analysis or to other related medical research [45].
The Protection of Personal Information Act (2003) is also
applicable to the conduct of human genome research,
reflecting public awareness of privacy protection [46].
Under this legislation, de-identified genetic information
is considered to be personal information as long as the
means of re-identification (such as the correspondence
table linking samples to original sample donors) is kept
in the same institution where the genomic data are han-
dled. In the latest Genome Guidelines revised in 2013,
ERCs play a more crucial role in several key decisions
on the scope of informed consent, the use of existing
samples and the return of research results to sample do-
nors. The Medical University Ethics Review Committee
Association, administrated in the Life Science and
Bioethics Research Center, Tokyo Medical and Dental
University, has facilitated practical information exchange
between ERC members since 1988.
There are several organizations that manage large-
scale biobanks. The most internationally recognized of
them is Biobank Japan [25], and its first cohort com-
prised samples collected from 200,000 patients. The
National Center Biobank Network (NCBN) [26], which
includes the six national centers, has started to
integrate their activities and to accelerate the efficient
use of the collected samples. Similar to national
databases, the Japanese Genotype-phenotype Archive
(JGA) [24] was created in 2013 to share personally
identifiable genotype and phenotype data, and this is
conducted in partnership with the National Bioscience
Database Center (NBDC) and the DNA Data Bank of
Japan (DDBJ).
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human genome research: recruitment of healthy indivi-
duals, policymaking for returning results, and links
between genetics databases and electronic health records
(EHRs). In Japan, much of the early genomic research
involved associational analysis that linked human ge-
nome sequences with particular diseases. In recent years,
the Japanese government has, in collaboration with Bio-
bank Japan, NCBN and ToMMo, increasingly invested
in genome cohort studies and biobanks for the develop-
ment of a comprehensive database for populations, in-
cluding healthy individuals, by integrating health and
lifestyle data with data from genomic and proteomic
analysis. To facilitate such research, the government
continues discussion on the introduction of a law relat-
ing to the utilization and protection of EHRs under
on-goingreforms on tax and social security. Another
important consideration is that public trust and engage-
ment generally need to be improved, especially following
the catastrophic earthquake and tsunami in 2011.
Singapore
A number of research institutes operating under the
Agency for Science, Technology and Research (A*STAR)
conduct a range of human genomic research in
Singapore, including the Genome Institute of Singapore,
the Bioinformatics Institute, and the Bioprocessing
Technology Institute (Table 1). There are also univer-
sities, medical research institutions and major research
hospitals undertaking different types of genomic re-
search. An initial attempt to establish a national biobank
in 2011 was not successful because of underutilization
and the financial burden of maintenance [47]. Instead,
major healthcare and research institutions continue to
be the key repositories of biomaterials, and these are ac-
cessible to researchers (subject to certain requirements,
including IRB approval). Although not an exclusively
genomic database, the National Registry of Diseases
Office is a repository of data that has been used for
genetic research.
The Bioethics Advisory Committee (BAC) is a high-
level expert body that advises the government on ethical,
legal and social issues that arise from biomedical re-
search. It was established in 2000 as a policy measure to
safeguard the reputation of scientific work and medical
services in Singapore. Since then, the BAC and govern-
ment agencies (especially the Ministry of Health) have
established a general ethical and regulatory framework
to ensure appropriate oversight whilst avoiding the over-
regulation of research. The National Registries of Disease
Act was enacted in 2007, to a large degree attributable to
a recommendation of the BAC to provide a firm legal
footing for disease registries that use personal informa-
tion in public health research. This recommendationwas published in a report by the BAC on the use of per-
sonal information (which includes genetic information)
in biomedical research [48]. The Personal Data Protection
Act was enacted in 2012. The legislative provisions are
broadly similar to those of the Data Protection Act of the
UK, and informed consent is emphasized for the use of
personal information in research [49].
Within this ethico-legal framework, all human genetic
research requires the approval of an appropriately con-
stituted IRB. Participation in research must be on a vol-
untary and informed basis, and consent is required from
the person from whom biological material was obtained
or to whom identifiable information (including genetic
information) relates [50]. As a general requirement,
identifiable information that is used for research should
be de-identified as far and as early as possible, and
should be stored or transferred as de-identified informa-
tion. However, personal information that has been irre-
versibly de-identified need not be subject to privacy and
confidentiality requirements. Where applicable, privacy
and confidentiality safeguards should be commensurate
with the potential risk of harm from disclosure, and
should be proportional to the sensitivity of the informa-
tion and the kind of research being carried out [48,51].
The general framework serves to set out baseline stan-
dards for IRB members and researchers, but there are
institutional variations as academic, healthcare and
research institutions are free to adopt more stringent
ELSI requirements and practices.
At the national level, concerns over conflicts of inter-
est have been raised due to a growing emphasis on in-
dustrial collaboration and commercialization of research.
These could even discourage participation in research.
In addition, there is no anti-discrimination legislation in
Singapore, and this could also discourage some individ-
uals from undergoing genetic testing, whether for re-
search or for medical purposes. There are also concerns
with the application of whole genome and exome
sequencing for research and medical purposes. The BAC
and Singapore’s Ministry of Health are in the process of
updating existing guidelines on genetic testing, genetic
research and biobanking.
South Korea
The Korea Centers for Disease Control and Prevention
(KCDC), a government agency belonging to the Ministry
of Health and Welfare (MoHW), is the leading institu-
tion on the use, management and storage of human gen-
ome materials or genomic information in South Korea.
The Korean National Institute of Health (KNIH) is the
primary national research agency in Korea, and is also
responsible for genomic databases and biobanks
(Table 1). The KNIH initiated the Korea Biobank Project
(KBP) in 2008, including the establishment of the
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banks [27]. Through the KBP, the NBK has collected
human biospecimens, consolidating them with donor
clinical records, and shares them with biomedical
researchers [28].
There are a number of regulations relating to human
genome research and biobanks (Table 2). The most rele-
vant legislation is the Bioethics and Biosafety Act (BBA),
which was enacted in 2005 and fully revised in 2013.
This act is generally applicable to all human subject re-
search, genomic research, genetic testing, biobanks, stem
cell research and embryonic research. In 2011, the
Guidelines for Protecting Personal Information in Medical
Institutions were approved by the Ministry of Public
Administration and Security (MoPAS) and MoHW. Sub-
sequently in 2013, the Guidelines for Protecting Genomic
Information were developed by the Center for ELSI
Research as a part of the National Project for Personalized
Genomic Medicine 21 (PGM21) [32], in South Korea.
The BBA categorizes human samples (such as tissues,
cells, blood and body fluids) and their components (such
as serum, plasma, chromosomes, DNA and RNA) as
human derivatives and sets regulations on human deriv-
atives research. This categorization reflects the differ-
ences between genetics-related research and human
subject research. The BBA has specified the establish-
ment, role and organization of the National Bioethics
Committee and the IRBs. The National Bioethics Com-
mittee is the highest level expert body designated by the
President of South Korea. IRBs should be established in
hospitals and research institutions that are involved in
human subject research, stem cell and biospecimen re-
search, genetic testing and biobanks. IRBs review the
ethical and scientific validity of research protocols.
Review for genomic research can be applied either
through a fast or regular track, depending on whether
human participants are involved. In 2002, IRB members
founded the Korean Association of Institutional Review
Boards (KAIRB) under the auspices of the Korean Academy
of Medical Sciences [52]. By law, informed consent is
generally required for the donation of human materials.
The BBA Enforcement Rule provides the guidelines for
official informed consent forms for donations as well as
genetic tests.
As a recent public survey demonstrated, the develop-
ment of professional genetic counseling is urgently re-
quired to improve the general population’s understanding
of genomic medicine. After revision of the BBA, individual
hospitals and research institutions are required to decide
whether they will discard preserved biospecimens or
transfer them to NBK after a fixed period. However, there
are growing demands to expand the opportunities of re-
searchers to access and distribute the qualified biospeci-
mens with their associated data in NBK. In addition,direct-to-consumer genetic testing services now abound
and they illustrate many loopholes in the BBA, which
otherwise provides a very strict list of permissible genetic
tests.
Taiwan
Major research institutes conducting genome research in
Taiwan include the Genomics Research Center (GRC) of
the Academia Sinica, the National Health Research
Institute (NHRI) and five National Centers of Excellence
for Clinical Trials and Research established in university
hospitals and sponsored by the Ministry of Health and
Welfare (MOHW) (Table 1).
The Human Biobank Management Act (HBMA) was
established in 2010 to regulate biomedical and genetic
research and to ensure protection of human subjects.
HBMA set out very detailed processes that must be ob-
served in taking informed consent [33]. The Human
Subjects Research Act (HSRA, 2011) even requires the
Research Ethics Committee (REC) or IRB to be accre-
dited by the MOHW first, before it can start reviewing
research protocols. The National Accreditation Program
for RECs and IRBs was started in 2004, and it is now
compulsory for the institutional REC or IRB to receive
regular visits and accreditation from the MOHW. Many
RECs or IRBs in Taiwan have joined the FERCAP net-
work, and 23 have been recognized by its SIDCER pro-
gram. In comparison to other Asian countries, Taiwan
has passed many legal regulations and policies to govern
human and biobank research in recent years, which have
raised potential conflicts between advancing biomedical
or genomic research and protecting human subjects.
Nonetheless, ELSI scholars of the National Research
Program for Biopharmaceuticals (NRPB) have worked
on mitigating such unnecessary conflict by improving
clarity in legal and policy requirements, and by facilitat-
ing public consultation and engagement. The HBMA
and HSRA restrict broad consent because these are not
considered to provide enough information for the re-
search subjects to consider and consent to. Consent is
mostly directed at specific biomedical research and
broad consent is allowed only in exceptional cases and
after scientific and ethical reviews. Consent for the use
of existing tissues is a major challenge in Taiwan. Conse-
quently, RECs or IRBs play important roles in deciding
the scope, feasibility and authorization of consents for
leftover samples and in determining whether re-consent
is required on a case-by-case basis.
The Taiwan Clinical Trials Consortium (TCTC),
involving a dozen research institutions, has developed
research collaborations and approaches for data sharing
for major diseases. The Taiwan Biobank was launched in
2005 as part of Taiwan’s strategy to promote biomedi-
cine and technology [29]. However, this project has been
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and legal scholars who have expressed concerns about
genetic privacy, informed consent, linkage of databases,
conflict of interest, procedural justice, and legitimacy of
technology policymaking [53]. This has resulted in rigor-
ous legislative and regulatory requirements as reflected
in the HBMA and HRSA, which have limited the devel-
opment of similar tissue storage or biobanking ap-
proaches and the access and utilization to such samples
for the last few years.
Other ELSI issues of current interest in Taiwan include
benefit sharing, return of and access to research results,
workplace genetic discrimination, indigenous population
research, commercialization of genetic testing, and
issues related to big data research for healthcare.
Comparing ELSI practices in East Asia
Here, we compare the ELSI practices and policies for
human genomic research in the six East Asian countries,
discussing research infrastructure, regulatory frame-
works, ethics review and informed consent. We consider
the local concerns and national interests, and the impli-
cations for wider research collaboration and public
participation.
Research infrastructure
Many of the large-scale genomic research initiatives in
East Asia considered here are driven by interests defined
by the state. This may indicate that researchers in these
countries are less empowered to pursue research inter-
ests independently, when compared with their colleagues
in Western countries. However, the globalization of gen-
omic research could enable East Asian researchers to by-
pass their local academic societies and possibly national
commitments [54] in favor of participation in inter-
national efforts like the Human Genome Organization
(HUGO) [55] and the ICGC, and in Pan-Asian genomics
initiatives like the HUGO Pan-Asian Population Genom-
ics Initiative (PAPGI) [56], HUGO Pan-Asian SNP
Consortium (PASNP) [20], the Asia Cohort Consortium
[57], and Asia Pacific Society of Human Genetics
(APSHG) [58]. Differing national interests have also re-
sulted in different research infrastructures and establish-
ments (Table 1). Governments in Japan and Taiwan have
promoted comparable large-scale genotyping initiatives
over the past decade, but the aims are different. Japanese
initiatives are aimed at the making of science by and for
the Japanese, whereas Taiwan’s initiatives convey a less
pronounced message of nationalism [59].
Regulatory frameworks
While many of the East Asian countries regulate in-
formed consent, biobanking, sample sharing, material
transfer, and ethics review of research (Tables 1 and 2),the regulations are not any more or less onerous than in
Western countries. In general, regulatory control of bio-
medical research in East Asia has been indirect, encom-
passing guidelines that may not have any legal support.
There is also wide variation in the manner and extent to
which civil liberties are safeguarded. In Europe, the Oviedo
Convention on Human Rights and Biomedicine has been
very influential in promoting legislative initiatives against
genetic discrimination in most of the European countries
[60], but only a few East Asian countries have similarly
targeted safeguards. In South Korea for instance, genetic
discrimination is prohibited by legislation. However, there
are built-in flexibilities that allow the use of genetic test
results for future scientific developments, and it is in this
regard less restrictive than the Oviedo Convention [61]. In
Indonesia, safeguards against discrimination are directed
at race and ethnicity rather than genetics per se, but they
have been criticized as narrow by human rights groups
[62]. These cases illustrate that political and cultural sensi-
tivities or concerns, rather than research goals and
initiatives, have shaped the scope of legislation on anti-
discrimination. There are exceptions, where legislation
has been targeted at specific research areas or practices
regarded to be of particular concern or of national inter-
est. For instance, many Asian countries have legislative
safeguards for the use of personally identifiable informa-
tion in research. These could, to some degree, be attrib-
uted to political pressure from Europe, and primarily the
Data Protection Directive of the European Union [63]. In
Indonesia, concerns over biopiracy have led to the enact-
ment of the Health Law and the pronouncement of
Ministry of Health regulations that give emphasis to safe-
guarding national sovereignty, especially in relation to bio-
logical resources and benefit sharing at a country level.
These differences in ELSI practices are again more likely a
consequence of socio-political concerns that are country-
specific, rather than local application of universal ethical
requirements [64].
Ethics review and informed consent
In the United States of America (USA), IRBs review re-
search proposals to ensure that they adhere to federal
regulations for federally funded research. Modeled after
this system, the establishment of IRBs or RECs for gen-
omic research is based on regulations and guidelines in
China, Indonesia, Japan and Singapore and on laws in
South Korea and Taiwan. However, the application of
these regulations and guidelines vary considerably in dif-
ferent institutions, as in the USA [65]. Common issues
with regard to IRBs or RECs include the education and
qualification of its members and the appropriate super-
vision of their work. In order to raise the quality of re-
view, IRBs or RECs in Indonesia and Taiwan are under
the supervision of government authorities and some
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dited under internationally recognized standards. Other
East Asian countries have introduced annual evaluations
(China), facilitated knowledge exchange with other
board members (Japan, South Korea), and published de-
tailed guidelines on the constitution, accreditation and
operation of the boards (Singapore). Similar to the USA,
differing standards have contributed to conflicts between
IRBs or RECs and researchers [65-67].
Although gaining informed consent at an individual
level is increasingly being emphasized in many East
Asian countries, it continues to be a collective process in
practice, where consent would also involve the research
participant’s family members or members of his or her
broader community [68]. As outlined above, this is par-
ticularly so in countries with a sizeable number of differ-
ent ethnic minorities, such as China and Indonesia.
However, the trend is that emphasis on individual
decision-making at an individual level will continue to
grow, and the conventional view of East Asian countries
as being more family- or community-centered and less
focused on individuals relative to Western societies may
not be sustainable in the long run [69]. Regarding left-
over tissue samples, there is also growing acceptance of
general consent for their use in research, provided that
appropriate safeguards are in place. Therefore, when
comparing ELSI practices in East Asian and Western
countries, a more accurate and up-to-date view may be
that ethical, legal and social concerns that arise from
genetic or genomic research are often shared, although
differences arise in emphasis and approach. Another
issue is the difficulty of ensuring that sample donors
have acted voluntarily and on an informed basis. In
some of the local communities and hospitals, resource-
poor donors who may also be illiterate or uneducated
are at risk of exploitation, particularly if refusal to con-
tribute a sample is understood as denial of access to
treatment.
Whether in East Asian or Western countries, a com-
mon lesson is that ethics review and informed consent
need to be customized to the local contexts. Where re-
search and policy experts in East Asia have been quick
to embrace the Western and ‘international’ ELSI con-
cepts and practices, there is now growing tension be-
tween these concepts and practices and those that arise
from indigenous values. Arguably, the alleviation or
resolution of such tensions necessitates the involvement
of a broader range of interested stakeholders.
Implications for research collaboration and public
participation
In a number of East Asian countries, a combination of
national interests and the hope of therapeutic benefit
have been relied upon to garner public participation aswell as support for particular, often large-scale, research
initiatives. However, the failure to complement these ini-
tiatives with substantive public engagement might have
led to public distrust in China, South Korea, Taiwan and
Japan. In South Korea, national biobanks require that re-
searchers be permitted to access and distribute the
qualified biospecimens with their associated data. In
Taiwan, the monopoly of authority (currently comprising
a body of academic and technical experts) over the
Taiwan Biobank has fostered tensions and widespread
distrust, aggravated by a lack of open communication
[70,71]. A similar lack of public trust is evident in Japan.
Surveys showed that while a majority of the public ap-
proves of the promotion of genomic studies [72], public
trust in science was damaged by events following the
earthquake, tsunami and subsequent nuclear accident in
2011 [73]. In Singapore, the ethical evaluation of research
initiatives is similarly expert driven, although it has a more
consultative character as the national bioethics body has
sought feedback from the relevant stakeholders and/or the
general public on all of its deliberations and recommenda-
tions to the government. Some have observed that public
discourses around science policies exist in Singapore but
are limited by a lack of plurality and diversity of the par-
ticipant communities [74].
Conclusions and future directions
Many of the large-scale genomic research initiatives in
East Asia are driven by national interests, and so differ-
ences in ELSI practices between countries are more
likely to be a consequence of country-specific concerns.
It is not unusual to find elements of Western or inter-
national governance approaches operating alongside
more parochial ELSI practices in East Asian countries.
Hence, regulatory control over biomedical research in
these countries has a relatively mixed character, with dir-
ect oversight of some aspects and little or no control
over others. In contrast, regulatory environments in
Western countries (with the possible exception of the
USA) have a more consistent legal character. Individual
consent is increasingly highlighted and strictly followed
as a matter of practice in East Asia, whereas some
Western countries are attempting to relax informed con-
sent as a strict requirement to facilitate scientific progress
[75,76]. The absence of consistent ethical standards
between the international research environment and
national ones (as well as among local research institutions
in some countries) could lead to conflicts and in the long
run reduce public trust in East Asia.
To address these problems, East Asian countries
should facilitate wider collaboration and public partici-
pation as well as appropriate training and supervision of
IRBs or RECs to work towards harmonizing ELSI
standards and practices. Where appropriate, more needs
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involved as long-term interactive partners, as has been
initiated in Western countries [77]. Ultimately, further
understanding of the interactive dynamics between the
global research agenda and shared local concerns will be
needed to facilitate the wider involvement of East Asian
countries in international genomic research. In addition,
there is a need to promote public trust in research more
generally through the consistent application of ethical
and regulatory requirements, public engagement and
cross-border collaborations. Further efforts will also be
needed to understand ELSI practices and regulations in
other countries in these and other global regions to
promote international collaboration in human genomic
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